Age-related atrophy is a growing problem, but there are no biomarkers, no medicines, the trials aren’t working and the data aren’t good enough.
started Entelo Bio to solve this, with a novel biobank and an obsessive focus on patients.
03:20 Origination of Entelo Bio
08:30 The focus on muscle, atrophy, and intrinsic capacity
13:48 Make something patients want
17:00 Drugs need to be safe, selective, and simple
19:10 Entelo’s biobank, platform and the focus on function
24:13 The musculoskeletal system is >40% of bodyweight and <1% of data
25:35 Figuring out the heterogeneity of disease
28:30 Bimagrumab
30:50 GLP1s
36:13 Peptides, BPC-157 and the ne1study
41:38 The diseases that piss people off
43:50 Surrogate endpoints for long-term trials
47:15 High-quality bio data in the AI era
54:54 Automated labs
1:01:54 Exciting future companies and ideas
This post is sponsored by Consensus, the AI agent for research that now has >2.5 million monthly users (me included!). If you’re a doctor, try Medical Mode to query guidelines and the top medical journals. If you’re doing research, Consensus has access to 220 million peer-reviewed papers, and has deals with 6 top publishers to access full texts (even behind paywalls). You can use my link for a free trial!
Thank you for listening! Please reach out to Peter or me to discuss anything further.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.